How can transforming growth factor beta be targeted usefully to combat liver fibrosis?

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 2, 2004, Pages 123-126

  Shek, Fanny W ^a   Benyon, R Christopher ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antifibrotic; Collagen; Connective tissue growth factor; Extracellular matrix; Fibrosis; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinases; Transforming growth factor beta

Indexed keywords

CYTOKINE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TGFB1 PROTEIN, RAT; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ARTICLE; CONNECTIVE TISSUE; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBRIN FORMATION; FIBROSIS; HOMEOSTASIS; LIVER FIBROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RAT; TRANSGENIC ANIMAL; UPREGULATION; ANIMAL; EXPERIMENTAL LIVER CIRRHOSIS; HUMAN; METABOLISM; MOUSE; NOTE; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; RATS; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 2642585736     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200402000-00001     Document Type: Article

References (21)

1. Schnur J, Oláh J, Szepesi A, Nagy P, Thorgeirsson SS. Throacelamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004; 16:127-133.
2. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 1996; 54:339-45.
3. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999; 30:48-60.
4. Ueberham E, Low R, Ueberham U, Schonig K, Bujard H. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 2003; 37: 1067-1078.
5. Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats - usefulness and reliability of this animal model. Exp Pathol 1988; 34:229-236.
6. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 1999; 96:2345-2349.
7. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995; 92:2572-2576.
8. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999;96:12719-12724.
9. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999; 276:G1059-G1068.
10. Kanzler S, Meyer E, Lohse AW, Schirmacher P, Henninger J, Galle PR, et al. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 2001; 20:5015-5024.
11. Okuno M, Akita K, Moriwaki H; Kawada N, Ikeda K, Kaneda K, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120:1784-1800.
12. Bottinger EP, Letterio JJ, Roberts AB. Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int 1997; 51:1355-1360.
13. Boivin GP, O'Toole BA, Orsmby IE, Diebold RJ, Eis MJ, Doetschman T, et al. Onset and progression of pathological lesions in transforming growth factor-beta 1-deficient mice. Am J Pathol 1995; 146:276-288.
14. Crean JK, Lappin D, Godson C, Brady HR. Connective tissue growth factor: an attractive therapeutic target in fibrotic renal disease. Expert Opin Ther Targets 2001; 5:519-530.
15. Shek FW, Benyon RC, Walker FM, McCrudden PR, Pender SL, Williams EJ, et al. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am J Pathol 2002; 160:1787-1798.
16. Benyon RC, Novell CJ, Da Gaca M, Jones EH, Iredale JP, Arthur MJ. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999; 30:977-986.
17. Theret N, Lehti K, Musso O, Clement B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 1999; 30:462-468.
18. Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, Klein R, et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002; 277:3606-3613.
19. Issa R, Zhou X, Trim N, Millward-Sadler H, Krane S, Benyon C, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCI4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003; 17:47-49.
20. Ritter SJ, Davies PJ. Identification of a transforming growth factor-betal/ bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. J Biol Chem 1998; 273:12798-12806.
21. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002; 368:377-396.